Plasma Fractionation Market Analysis
The Plasma Fractionation Market, valued at USD 33.47 billion in 2023, is projected to reach USD 63.82 billion by 2031, growing at a CAGR of 8.4% during the forecast period (2024-2031).
Market Drivers
-
Increasing Demand for Plasma-derived Medicines:
- Driven by the rising prevalence of chronic diseases.
-
Technological Advancements:
- Continuous improvements in plasma fractionation technologies enhance product safety and efficacy.
-
Growing Geriatric Population:
- Higher susceptibility to chronic diseases among the elderly boosts demand for plasma-derived therapies.
-
Increasing Healthcare Awareness:
- Rising awareness and improved healthcare access in developing regions contribute to market growth.
Get Free Sample Copy of Report: https://www.snsinsider.com/sample-request/2992
Regional Growth Dynamics
-
North America:
- Dominates the market with leading plasma fractionation companies, advanced healthcare infrastructure, and high demand for plasma-derived medicines.
-
Europe:
- Experiencing significant growth due to the increasing prevalence of chronic diseases, rising healthcare investments, and supportive government initiatives.
-
Asia-Pacific:
- Expected to grow rapidly driven by a rising geriatric population, increasing healthcare spending, and greater awareness of plasma-derived therapies.
Key Market Players
- CSL Limited
- Grifols, S.A.
- Shire plc (Takeda Pharmaceutical Company Limited)
- Octapharma AG
- Kedrion S.p.A.
Future Outlook
The Plasma Fractionation Market is poised for robust expansion, driven by increasing demand for plasma-derived medicines, advancements in fractionation technologies, and improved healthcare access. Ongoing innovations in purification processes and product development are expected to enhance treatment options for various diseases and disorders.
Other Related Reports
Topical Drug Delivery Market Growth
